These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 31542942)

  • 1. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
    Neves JS; Leite AR; Mentz RJ; Holman RR; Zannad F; Butler J; Packer M; Ferreira JP
    Eur J Heart Fail; 2024 Oct; ():. PubMed ID: 39381950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
    Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
    Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
    Mentz RJ; Bethel MA; Merrill P; Lokhnygina Y; Buse JB; Chan JC; Felício JS; Goodman SG; Choi J; Gustavson SM; Iqbal N; Lopes RD; Maggioni AP; Öhman P; Pagidipati NJ; Poulter NR; Ramachandran A; Reicher B; Holman RR; Hernandez AF;
    J Am Heart Assoc; 2018 Oct; 7(19):e009304. PubMed ID: 30371301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
    Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Davis TME; Giczewska A; Lokhnygina Y; Mentz RJ; Sattar N; Holman RR;
    Cardiovasc Diabetol; 2022 Jun; 21(1):116. PubMed ID: 35761271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Reed SD; Li Y; Dakin HA; Becker F; Leal J; Gustavson SM; Kartman B; Wittbrodt E; Mentz RJ; Pagidipati NJ; Bethel MA; Gray AM; Holman RR; Hernandez AF;
    Diabetes Care; 2020 Feb; 43(2):374-381. PubMed ID: 31806653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
    Barbery CE; Giczewska A; White J; Lokhnygina Y; Mentz RJ; Holman RR; Pagidipati N; Hernandez AF; Jones WS
    Am Heart J; 2021 Sep; 239():59-63. PubMed ID: 33905751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
    Oulhaj A; Aziz F; Suliman A; Eller K; Bentoumi R; Buse JB; Al Mahmeed W; von Lewinski D; Coleman RL; Holman RR; Sourij H
    Diabetes Obes Metab; 2024 Oct; 26(10):4602-4612. PubMed ID: 39086032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Mentz RJ; Bethel MA; Gustavson S; Thompson VP; Pagidipati NJ; Buse JB; Chan JC; Iqbal N; Maggioni AP; Marso SP; Ohman P; Poulter N; Ramachandran A; Zinman B; Hernandez AF; Holman RR
    Am Heart J; 2017 May; 187():1-9. PubMed ID: 28454792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
    Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
    Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.